Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTS three-step adjuvant chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancer
ChiCTR-IPR-15007154Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, cyclophosphamide, etoposide and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: overall survival. Planned start Nov 2015; status: not yet recruiting.
02
Drugs
paclitaxelcyclophosphamideetoposidecarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR-IPR-15007154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007154.